Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gorlin Syndrome Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

NCT02828111
View directory record Official record
Conditions
Basal Cell Carcinomas
Interventions
Patidegib, Vehicle gel
Drug
Lead sponsor
PellePharm, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

NCT02303041
View directory record Official record
Conditions
Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
Interventions
Buparlisib, Sonidegib
Drug
Lead sponsor
Anne Chang
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

NCT03703310
View directory record Official record
Conditions
Basal Cell Nevus Syndrome
Interventions
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Redwood City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Isotretinoin in Preventing Skin Cancer

NCT00025012
View directory record Official record
Conditions
Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions
isotretinoin
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas

NCT02639117
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Vismodegib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

NCT02002689
View directory record Official record
Conditions
PTCH1 or SMO Activated Solid and Hematologic Tumors
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Greenwood Village, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

NCT03467789
View directory record Official record
Conditions
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions
Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

NCT00489086
View directory record Official record
Conditions
Neoplastic Syndrome
Interventions
tazarotene
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

NCT04893486
View directory record Official record
Conditions
BCCs in Gorlin Syndrome Patients
Interventions
PTX-022, Vehicle comparator
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer

NCT01463709
View directory record Official record
Conditions
Basal Cell Carcinomas
Interventions
PulseCure pulse generator and Derm-pulse electrode
Device
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

NCT01893892
View directory record Official record
Conditions
Musculoskeletal Complications
Interventions
levocarnitine, placebo, questionnaire administration
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

NCT02354261
View directory record Official record
Conditions
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Interventions
SUBA-Itraconazole
Drug
Lead sponsor
HedgePath Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Oceanside, California • Ormond Beach, Florida • Warren, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

NCT01815840
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Vismodegib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Suspended Phase 1Phase 2 Interventional

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

NCT03208296
View directory record Official record
Conditions
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Interventions
ASN-002
Biological
Lead sponsor
Ascend Biopharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

NCT00957229
View directory record Official record
Conditions
Basal Cell Nevus Syndrome, Gorlin Syndrome
Interventions
GDC-0449
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
35 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting Phase 1 Interventional

Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas

NCT06623201
View directory record Official record
Conditions
Basal Cell Carcinoma (BCC)
Interventions
aminolevulinic acid HCL (ALA), BLU-U device model 4170E
Drug · Device
Lead sponsor
Nathalie Zeitouni
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome

NCT02157623
View directory record Official record
Conditions
Basal Cell Nevus Syndrome
Interventions
Levulan, Red Light PDT, Blue Light PDT
Drug · Other
Lead sponsor
Edward Maytin, MD, PhD
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting No phase listed Observational

Primordial Dwarfism Registry

NCT04569149
View directory record Official record
Conditions
MOPDII, Meier-Gorlin Syndrome, Saul-Wilson Syndrome, Microcephalic Primordial Dwarfism, IMAGe Syndrome, RNU4atac-opathy (e.g MOPDI, Lowry-Wood Syndrome, and Roifman Syndrome), LIG4 Syndrome
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

NCT01556009
View directory record Official record
Conditions
Basal Cell Nevus Syndrome, Gorlin's Syndrome
Interventions
Vismodegib, Aminolevulinic acid %20 topical solution
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 23, 2026, 4:19 PM EDT
Completed No phase listed Observational

The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases

NCT00005660
View directory record Official record
Conditions
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 4:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions

NCT01014819
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Not listed
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

NCT04155190
View directory record Official record
Conditions
Recurrent Basal Cell Carcinoma
Interventions
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Apple Valley, California • Colton, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 4:19 PM EDT